Moxidectin versus Ivermectin in the prevention and treatment of acute and chronic experimental trichinellosis

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-05-11 DOI:10.1016/j.exppara.2024.108775

Dalia A. Elmehy , Ghada A. Gamea , Dina M. El-Guindy , Dina M. Tahoon , Reem A. Elkholy , Hager S. Zoghroban

{"title":"Moxidectin versus Ivermectin in the prevention and treatment of acute and chronic experimental trichinellosis","authors":"Dalia A. Elmehy , Ghada A. Gamea , Dina M. El-Guindy , Dina M. Tahoon , Reem A. Elkholy , Hager S. Zoghroban","doi":"10.1016/j.exppara.2024.108775","DOIUrl":null,"url":null,"abstract":"<div><p>The limited activity of the traditional medications against <em>T. spiralis</em> encysted larvae handicaps complete cure of trichinellosis till now due to decreased permeability and absorption through tissues. MOX is listed worldwide for prevention and treatment of several internal and external nematodes. Consequently, the aim of this work was to investigate the effect of moxidectin versus ivermectin on experimental acute and chronic trichinellosis and to illuminate the potential mechanisms of their effects. 105 Mice were divided into four groups; Group I: Uninfected healthy control; Group II: Infected untreated control; Group III: Infected and treated with IVM and Group IV: Infected and treated with MOX. The groups (II, III and IV) were later subdivided equally into three subgroups (a, b, and c) according to the stage of treatment. Parasitological counting of adults and larvae besides immune-histopathological examination of intestines and muscles were done. Results exhibited that both IVM and MOX succeeded in reducing adults and larvae counts with higher potential of MOX in both intestinal and muscle phase. The preeminence of MOX was indicated by decreased inflammation, a significant reduction in the microvascular density (CD31 immunostaining) as well as a reduction in the percentage of fibroblast activation protein (FAP) immunostaining in muscle tissues. Accordingly, the current work recommends moxidectin as an innovative treatment for trichinellosis.</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001448942400078X","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

The limited activity of the traditional medications against T. spiralis encysted larvae handicaps complete cure of trichinellosis till now due to decreased permeability and absorption through tissues. MOX is listed worldwide for prevention and treatment of several internal and external nematodes. Consequently, the aim of this work was to investigate the effect of moxidectin versus ivermectin on experimental acute and chronic trichinellosis and to illuminate the potential mechanisms of their effects. 105 Mice were divided into four groups; Group I: Uninfected healthy control; Group II: Infected untreated control; Group III: Infected and treated with IVM and Group IV: Infected and treated with MOX. The groups (II, III and IV) were later subdivided equally into three subgroups (a, b, and c) according to the stage of treatment. Parasitological counting of adults and larvae besides immune-histopathological examination of intestines and muscles were done. Results exhibited that both IVM and MOX succeeded in reducing adults and larvae counts with higher potential of MOX in both intestinal and muscle phase. The preeminence of MOX was indicated by decreased inflammation, a significant reduction in the microvascular density (CD31 immunostaining) as well as a reduction in the percentage of fibroblast activation protein (FAP) immunostaining in muscle tissues. Accordingly, the current work recommends moxidectin as an innovative treatment for trichinellosis.

Abstract Image

查看原文本刊更多论文

莫西菌素与伊维菌素在预防和治疗急性和慢性实验性螺旋体旋毛虫病中的对比。

传统药物对旋毛虫包囊幼虫的活性有限，导致组织渗透性和吸收性降低，至今仍无法彻底治愈旋毛虫病。MOX 已被世界各国列为预防和治疗多种体内和体外线虫的药物。因此，本研究旨在探讨莫西菌素和伊维菌素对实验性急性和慢性毛线虫病的影响，并阐明其潜在的作用机制。105 小鼠被分为四组：I 组：未感染健康对照组；II 组：感染未治疗对照组；III 组：感染并用伊维菌素治疗组；IV 组：感染并用莫西菌素治疗组。随后，根据治疗阶段将各组（II、III 和 IV）平均分为三个亚组（a、b 和 c）。除了对肠道和肌肉进行免疫组织病理学检查外，还对成虫和幼虫进行了寄生虫计数。结果表明，IVM 和 MOX 都能成功减少成虫和幼虫数量，其中 MOX 在肠道和肌肉阶段的潜力更大。MOX 的优势表现在炎症的减少、微血管密度（CD31 免疫染色）的显著降低以及肌肉组织中成纤维细胞活化蛋白（FAP）免疫染色百分比的降低。因此，本研究建议将莫西菌素作为治疗毛霉菌病的一种创新疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.